

Special Issue

Monkeypox Vaccine Development and Vaccination Strategies

Message from the Guest Editors

Monkeypox is a zoonotic disease that was once endemic in west and central Africa, caused by the orthopoxvirus, monkeypox virus. However, recent cases have been confirmed in many nonendemic countries outside of Africa. The WHO declared the ongoing monkeypox outbreak to be a public health emergency of international concern on 23 July 2022. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets and via fomites such as towels and bedding. Strategies for prevention, such as the smallpox vaccine has been recommended in high-risk persons. Two vaccines are currently available, JYNNEOSTM (live, replication-incompetent vaccinia virus) and ACAM2000® (live, replication-competent vaccinia virus). The development of vaccines against the monkeypox virus and different vaccination strategies are urgently needed. In this context, this Special Issue invites you to submit your research related to scientific advances in the field of monkeypox vaccine development and vaccination strategies.

Guest Editors

Dr. Natalie Prow

Hull York Medical School, University of York, York, UK

Dr. Preethi Eldi

Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, Australia

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/188978

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).